デュピルマブの新興薬剤に関する洞察と市場予測：2032年

デュピルマブ（デュピクセント）は、インターロイキン（IL）-4受容体のα鎖を標的とするモノクローナル抗体です。TH2反応の主要な推進因子であるサイトカインIL-4およびIL-13の生物学的作用を阻害します。

デュピルマブは米国で、皮膚（外用）に使用する処方療法で良好なコントロールが得られない、または外用療法を使用できない中等度から重度のアトピー性皮膚炎（AD）の12歳以上の患者を治療するために承認されています。12歳以上の青少年においては、デュピルマブの投与は成人の監督下で行うことが推奨されています。

現在承認されている適応症に加え、RegeneronとSanofiは、ピーナッツアレルギー、イネ科植物アレルギーなど、アレルギー性炎症およびその他の2型炎症に起因する疾患に対する広範な臨床開発プログラムにおいてデュピルマブを検討しており、小児AD、小児喘息、好酸球性食道炎、慢性閉塞性肺疾患（COPD）、水疱性類天疱瘡、結節性痒疹、慢性自然じんま疹、アレルギー性気管支肺アスペルギルス症などを対象としています。

当レポートでは、主要7ヶ国におけるデュピルマブ市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 水疱性類天疱瘡に対するデュピルマブの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 デュピルマブ市場評価

• 水疱性類天疱瘡に対するデュピルマブの市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国における水疱性類天疱瘡に対するデュピルマブ市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Dupilumab, Clinical Trial Description, 2023
• Table 2: Dupilumab, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Dupilumab Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Dupilumab Market Size in the US, in USD million (2019-2032)
• Table 7: Dupilumab Market Size in Germany, in USD million (2019-2032)
• Table 8: Dupilumab Market Size in France, in USD million (2019-2032)
• Table 9: Dupilumab Market Size in Italy, in USD million (2019-2032)
• Table 10: Dupilumab Market Size in Spain, in USD million (2019-2032)
• Table 11: Dupilumab Market Size in the UK, in USD million (2019-2032)
• Table 12: Dupilumab Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Dupilumab Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Dupilumab Market Size in the United States, USD million (2019-2032)
• Figure 3: Dupilumab Market Size in Germany, USD million (2019-2032)
• Figure 4: Dupilumab Market Size in France, USD million (2019-2032)
• Figure 5: Dupilumab Market Size in Italy, USD million (2019-2032)
• Figure 6: Dupilumab Market Size in Spain, USD million (2019-2032)
• Figure 7: Dupilumab Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Dupilumab Market Size in Japan, USD million (2019-2032)

“"Dupilumab Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about dupilumab for bullous pemphigoid in the seven major markets. A detailed picture of the dupilumab for bullous pemphigoid in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the dupilumab for bullous pemphigoid. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the dupilumab market forecast analysis for bullous pemphigoid in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in bullous pemphigoid.

Drug Summary:

Dupilumab (Dupixent) is a monoclonal antibody targeting the α chain of the interleukin (IL)-4 receptor. It inhibits the biological effects of the cytokines IL-4 and IL-13, which are key drivers in the TH2 response (Sastre, 2018).

Dupilumab is approved in the US to treat patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies; for use with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid-dependent asthma in patients aged 12 years and older whose asthma is not controlled with their current asthma medicines; and for use with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. In adolescents 12 years of age or older, it is recommended that dupilumab be administered by or under an adult's supervision.

In addition to the currently approved indications, Regeneron and Sanofi are also investigating dupilumab in a broad range of clinical development programs for diseases driven by allergic and other Type 2 inflammation, including peanut allergy, grass allergy, AD in pediatric patients, asthma in pediatric patients, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), bullous pemphigoid (BP), prurigo nodularis, chronic spontaneous urticaria, and allergic bronchopulmonary aspergillosis.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the dupilumab description, mechanism of action, dosage and administration, research and development activities in bullous pemphigoid.
• Elaborated details on dupilumab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the dupilumab research and development activities in bullous pemphigoid across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around dupilumab.
• The report contains forecasted sales of dupilumab for bullous pemphigoid till 2032.
• Comprehensive coverage of the late-stage emerging therapies for bullous pemphigoid.
• The report also features the SWOT analysis with analyst views for dupilumab in bullous pemphigoid.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Dupilumab Analytical Perspective by DelveInsight

• In-depth Dupilumab Market Assessment

This report provides a detailed market assessment of dupilumab for bullous pemphigoid in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• Dupilumab Clinical Assessment

The report provides the clinical trials information of dupilumab for bullous pemphigoid covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for bullous pemphigoid is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence dupilumab dominance.
• Other emerging products for bullous pemphigoid are expected to give tough market competition to dupilumab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of dupilumab in bullous pemphigoid.
• Our in-depth analysis of the forecasted sales data of dupilumab from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the dupilumab in bullous pemphigoid.

Key Questions

• What is the product type, route of administration and mechanism of action of dupilumab?
• What is the clinical trial status of the study related to dupilumab in bullous pemphigoid and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the dupilumab development?
• What are the key designations that have been granted to dupilumab for bullous pemphigoid?
• What is the forecasted market scenario of dupilumab for bullous pemphigoid?
• What are the forecasted sales of dupilumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to dupilumab for bullous pemphigoid?
• Which are the late-stage emerging therapies under development for the treatment of bullous pemphigoid?

Table of Contents

1. Report Introduction

2. Dupilumab Overview in bullous pemphigoid

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Dupilumab Market Assessment

• 5.1. Market Outlook of Dupilumab in bullous pemphigoid
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Dupilumab in the 7MM for bullous pemphigoid
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Dupilumab in the United States for bullous pemphigoid
  • 5.3.2. Market Size of Dupilumab in Germany for bullous pemphigoid
  • 5.3.3. Market Size of Dupilumab in France for bullous pemphigoid
  • 5.3.4. Market Size of Dupilumab in Italy for bullous pemphigoid
  • 5.3.5. Market Size of Dupilumab in Spain for bullous pemphigoid
  • 5.3.6. Market Size of Dupilumab in the United Kingdom for bullous pemphigoid
  • 5.3.7. Market Size of Dupilumab in Japan for bullous pemphigoid

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options